RELMADA THERAPEUTICS INC (RLMD) — insider trading
Health Care · NASDAQ
RELMADA THERAPEUTICS INC (RLMD) has 20 reported SEC Form 4 insider transactions in our data, including 13 open-market purchases among the most recent 20 (latest 2026-09-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Shenouda Maged | Officer (Chief Financial Officer) | Open-market purchase | 79,800 | $4.25 | $339.1K | Form 4 |
| 2026-09-10 | TRAVERSA SERGIO | Director, Officer (Chief Executive Officer) | Open-market purchase | 100,000 | $4.10 | $410.0K | Form 4 |
| 2026-09-09 | Shenouda Maged | Officer (Chief Financial Officer) | Open-market purchase | 120,200 | $4.20 | $504.8K | Form 4 |
| 2026-09-09 | TRAVERSA SERGIO | Director, Officer (Chief Executive Officer) | Open-market purchase | 100,000 | $4.18 | $418.0K | Form 4 |
| 2025-12-15 | Shenouda Maged | Officer (Chief Financial Officer) | Open-market purchase | 11,665 | $4.12 | $48.1K | Form 4 |
| 2025-12-15 | TRAVERSA SERGIO | Director, Officer (Chief Executive Officer) | Open-market purchase | 27,500 | $4.12 | $113.3K | Form 4 |
| 2025-12-12 | CASAMENTO CHARLES J | Director | Grant / award / vesting (derivative) | 164,000 | — | $0 | Form 4 |
| 2025-12-12 | Kelly Paul Edward | Director, Officer (COO) | Grant / award / vesting (derivative) | 828,000 | — | $0 | Form 4 |
| 2025-12-12 | GLASSPOOL JOHN | Director | Grant / award / vesting (derivative) | 164,000 | — | $0 | Form 4 |
| 2025-12-12 | Fedeli Fabiana | Director | Grant / award / vesting (derivative) | 164,000 | — | $0 | Form 4 |
| 2025-12-12 | Ence Chuck | Officer (CA and CO) | Grant / award / vesting (derivative) | 828,000 | — | $0 | Form 4 |
| 2025-12-12 | Shenouda Maged | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 828,000 | — | $0 | Form 4 |
| 2025-12-12 | TRAVERSA SERGIO | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 1,198,000 | — | $0 | Form 4 |
| 2025-11-05 | Kelly Paul Edward | Director, Officer (Chief Operating Officer) | Open-market purchase | 90,000 | $2.20 | $198.0K | Form 4 |
| 2025-11-05 | TRAVERSA SERGIO | Director, Officer (Chief Executive Officer) | Open-market purchase | 272,500 | $2.20 | $599.5K | Form 4 |
| 2025-11-05 | Ence Chuck | Officer (CAO and COO) | Open-market purchase | 136,000 | $2.20 | $299.2K | Form 4 |
| 2025-11-05 | Shenouda Maged | Officer (Chief Financial Officer) | Open-market purchase | 500,000 | $2.20 | $1.10M | Form 4 |
| 2025-08-28 | TRAVERSA SERGIO | Director, Officer (Chief Executive Officer) | Open-market purchase | 55,976 | $0.74 | $41.4K | Form 4 |
| 2025-08-27 | TRAVERSA SERGIO | Director, Officer (Chief Executive Officer) | Open-market purchase | 129,455 | $0.67 | $86.7K | Form 4 |
| 2025-08-26 | TRAVERSA SERGIO | Director, Officer (Chief Executive Officer) | Open-market purchase | 80,545 | $0.62 | $49.9K | Form 4 |
Ask the chat about RLMD's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: RELMADA THERAPEUTICS INC (RLMD).
Last updated 2026-09-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.